CIDRAP

Trial: Paxlovid retreatment after COVID rebound tied to faster drop in viral RNA but no clinical benefit

Symptomatic or viral rebound is estimated to occur in 0.8% to 32% of Paxlovid recipients and 1.1% to 31% of those who receive ...
Medscape

GUCY2C Reverse Transcriptase PCR to Stage pN0 Colorectal Cancer Patients

Expert Rev Mol Diagn. 2009;9(8):777-785. Traditional paradigms for staging patients with colorectal cancer incorporating standard histopathological assessment of regional lymph nodes underestimate the ...
insider.si.edu

PCR applications : protocols for functional genomics / edited by Michael A. Innis, David H. Gelfand, John J. Sninsky

Pt. 1. Key concepts for PCR-- Ch. 1. Optimization of PCR: conversations between Michael and David-- Ch. 2. The convergence of PCR, computers, and the human genome project: past, present, and future-- ...
ascopubs.org

Human Epidermal Growth Factor Receptor 2 Assessment in a Case-Control Study: Comparison of Fluorescence In Situ Hybridization and Quantitative Reverse Transcription Polymerase ...

The optimal method to assess human epidermal growth factor receptor 2 (HER2) status remains highly controversial. Before reporting patient HER2 results, American Society of Clinical Oncology ...
The Scientist

Thermostable Reverse Transcriptase at Room Temperature

New England Biolabs (NEB®) announced today that they have released a novel, thermostable reverse transcriptase, WarmStart® RTx Reverse Transcriptase, specifically designed for nucleic acid detection.